Navigation Links
moksha8 Expands Alliance With Roche to Commercialize $200 Million of Products in Brazil and Mexico

MEXICO CITY, SAO PAULO and PHILADELPHIA, May 20 /PRNewswire/ -- moksha8, Inc. announced today that it has expanded its strategic partnership with Roche to commercialize an additional portfolio of products in Mexico currently generating sales of $140 million USD.

moksha8 will commercialize products in three therapeutic areas, CNS disease, anti-infectives, and inflammation. The product portfolio consists of well-known brands including Rivotril(R), Rocephin(R) and Bactrim(R).

"moksha8 has produced strong results for Roche in Brazil and we are delighted to expand our relationship to include Mexico as a key country in Latin America," said Ernest Egli, President of Roche Latin America. "moksha8 brings strong commercial capabilities and innovative marketing to our CNS, anti-infectives and inflammation franchises. We look forward to continuing this valuable relationship."

"moksha8 has established a broad footprint in Latin America with leading products that are cornerstones of medical care," said Simba Gill, CEO of moksha8. "We look forward to continuing our strong relationship with Roche and driving value from this important portfolio of products. We are now firmly positioned as the leading partner of choice for pharmaceutical and biotechnology companies looking to generate value across Latin America."

In just over a year, moksha8 has grown its commercial organization to over 200 employees in Brazil and Mexico and a portfolio of products with sales of $200 million USD. moksha8 is uniquely positioned as the leading specialty pharmaceutical company in Latin America with a strong presence in CNS, anti-infectives and inflammation.

moksha8 was founded in December 2006 by Simba Gill and Texas Pacific Group, and has raised significant financing from top-tier private equity firms, including Texas Pacific Group and Votorantim Novos Negocios, the venture capital and private equity arm of Votorantim, one of Brazil's largest privately held conglomerates. moksha8 is uniquely positioned as the partner of choice for both pharmaceutical and biotechnology companies seeking to capture value from their products in high growth emerging markets. moksha8 has established commercial operations in key geographies in Latin America including Sao Paulo and Mexico City, with corporate offices in Pennsylvania. moksha8 provides the highest quality medicines to the fastest growing markets of the world.

SOURCE moksha8, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Peter MacCallum Cancer Centre Expands Cancer Research Efforts with Automation Tool from Caliper Life Sciences
2. Water Street Healthcare Partners Expands Team With Senior Investment Professionals
3. Expands Values Counseling and Therapy Into Michigan, Florida, and Washington State
4. Shire Expands Gastrointestinal Patient Assistance Program for Uninsured or Unemployed Americans
5. Offit Kurman Expands into Bethesda
6. Cord Blood America CEO Matthew Schissler Expands on Thought Process in Owning Stem Cell Laboratory
7. Marina Medical Expands into Texas with Five Emergency Departments in San Antonio
8. CyberPower Systems Expands Market Presence by Signing Distribution Agreement with Tech Data
9. Ross University School of Medicine Expands Clinical Rotations on East Coast
10. Prepared Response, Inc. Expands Its Pandemic Planning and Response Offerings
11. NeoStem Files Patent Application for Cosmetic Stem Cell Face Lift Technology and Expands Stem Cell Collection Network into New Jersey
Post Your Comments:
(Date:11/27/2015)... ... , ... There is only one major question facing all law firms in ... question has not been an easy question to answer. Especially when the senior partners ... workforce don’t share the same discipline around working long hours. , In addition ...
(Date:11/27/2015)... ... 27, 2015 , ... According to an article published November 13th ... in Washington D.C. revolved around the fact that proper dental care, both at-home and ... the link between periodontal disease (more commonly referred to as gum disease) and diabetes. ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an ... the University of Toronto and the University of British Columbia suggested that laws requiring ... injuries. The article explains that part of the reason for the controversial conclusion is ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article ... the way that they are handling security in light of the recent terrorist attacks ... in an attempt to stop an attack from reaching U.S. soil. Especially around special ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... care in America. As people age, more care is needed, especially with Alzheimer’s, ... and medical professionals are being overworked. The forgotten part of this equation: 80 ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... , Nov. 27, 2015 Research and ... the "Global Intrauterine Devices Market 2015-2019" report ... --> In this report, the author the ... devices market for 2015-2019. To calculate the market size, ... following type of products: Hormonal IUDs and copper IUDs. ...
(Date:11/26/2015)... 26, 2015 Un nuevo enfoque ... para el cáncer avanzado.   --> ... fotodinámica de Bremachlorin para el cáncer avanzado.   ... inmunoterapia con la terapia fotodinámica de Bremachlorin para el ... . --> Clinical Cancer Research . ...
(Date:11/26/2015)... Nederland, November 26, 2015 ... Een nieuwe aanpak combineert immunotherapie met Bremachlorin-photodynamische ... ) --> ...      (Photo: ) ... Universitair Medisch Centrum (LUMC) blijkt ...
Breaking Medicine Technology: